Polyrizon Ltd.

In addition to Medigus' investment in Polyrizon, it has entered into an exclusive reseller agreement with Polyrizon. Medigus received an exclusive global license to promote, market, and resell the Polyrizon products, focusing on a unique Biogel to protect from the COVID-19 virus. The term of the license is for four years, commencing upon receipt of sufficient FDA approvals for the lawful marketing and sale of the products globally. Medigus also have the right to purchase the Polyrizon products on a cost-plus 15% basis for the purpose of reselling the products worldwide. In consideration of the license, Polyrizon will be entitled to receive annual royalty payments equal to 10% of Medigus' annualized operating profit arising from selling the products.